SEGLENTIS resources

The SEGLENTIS Risk Evaluation and Mitigation Strategy (REMS) Program

The benefits of treating acute pain with opioid analgesics should always outweigh the risks of addiction, abuse, and misuse. To ensure this, healthcare providers are strongly encouraged to do all of the following:

To obtain further information on the opioid analgesic REMS and for a list of accredited REMS continuing medical education/continuing education, call 1-800-503-0784, or log on to The FDA Blueprint can be found at

The SEGLENTIS® Savings Card

Using the SEGLENTIS® Savings Card, your eligible patients may pay as little as $25* for their SEGLENTIS prescription. Click here to learn more about the SEGLENTIS® Savings Card and print cards for your patients.

*Certain rules and restrictions apply.

CRYSTAL CLEAR: Education hub

Visit Crystal Clear to gain insight from experts and access helpful information about
SEGLENTIS and acute pain

See how SEGLENTIS performed in a Phase 3 clinical trial

Access the full report in Pain Practice to learn more about how SEGLENTIS demonstrated analgesic efficacy over 48 hours compared to tramadol hydrochloride, celecoxib, and placebo

Get important